The Symptoms Of Multiple Sclerosis Blog

The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS), according to a study to be published in the October 8, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study based in France involved 349 children with MS and 2,941 children without the disease. The children were all under the age of 16. A total of 24.

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint.

Data presented at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) demonstrated that early initiation of Betaseron(R) (interferon beta-1b) treatment had a greater impact on long-term outcomes, when compared to delayed treatment.

Bayer HealthCare Pharmaceuticals Inc. announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.

Results from a new study investigating the benefits of Sativex in neuropathic pain in people with multiple sclerosis (MS) have shown it gave long-term pain relief. The study followed 42 people with MS who took Sativex – a cannabis-based drug trialled by GW Pharmaceuticals. This

A drug used to increase blood production in both medical treatments and athletic doping scandals seems also to improve memory in those using it. New research published in the open access journal BMC Biology shows that the memory enhancing effects of erythropoietin (EPO) are not related to its effects on blood production but due to direct influences on neurons in the brain.

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, announced the establishment of a novel MS research partnership with the Myelin Repair Foundation, Inc. (MRF).

The MS Society has been chosen by the Department of Health from over 120 applications to participate in the testing phase of a new scheme to ensure good quality information across the health and social care sector. The information accreditation scheme will combat substantial variation in the quality of health and social care information available and will provide a way for the public and professionals to know that the information they are using is reliable.

Biogen Idec announced that enrollment is complete in the ASSURANCE trial, a long-term follow-up study which will assess up to 15 years of AVONEX® (interferon beta-1a) treatment in an effort to provide detailed data on the long term efficacy of the drug. ASSURANCE is a multi-center, open-label follow-up study of patients with relapsing multiple sclerosis (MS) treated with AVONEX or placebo for at least two years in the phase III pivotal trial.